Home » Diversifying Laboratory Services in the Post-COVID Era

Diversifying Laboratory Services in the Post-COVID Era

In a landscape marred by remarkable inflationary pressures, laboratories across the USA are confronting unforeseen financial hurdles. The surge in costs coupled with the diminishing prominence of COVID-19 testing has created an imperative for laboratories to explore new avenues for revenue generation. While the pandemic’s grip might be loosening, the resilience of laboratory technicians shines as they pivot towards diversification, finding solace in expanding their testing menu to sustain their operations.

Transitioning Beyond COVID-19 Testing

As the pandemic’s intensity wanes, so does the demand for COVID-19 testing. Laboratories that once thrived on the surge in testing are now grappling with a slowdown. In this pivotal juncture, laboratory technicians are adopting a forward-looking stance. They recognize the need to redefine their services and extend their capabilities to cater to a broader range of diagnostic needs.

Broadening Horizons: A Plethora of Diagnostic Possibilities

The path to sustainability lies in embracing diversity. By casting their net wider and offering a spectrum of diagnostic tests, laboratories can ensure a steady stream of clients and revenue. Jant Pharmacal, a leader in laboratory and diagnostics equipment, emerges as a guiding light, empowering laboratories to optimize performance and embark on an exhilarating journey of growth.

Exploring a Myriad of Testing Options

CLIA Moderate and High Complexity Clinical Labs

The comprehensive collection encompasses a wide variety of analyzers and reagents, meticulously tailored to meet the specific demands of CLIA Moderate and High Complexity toxicology labs. These solutions are thoughtfully designed to cater to the diverse needs of laboratory toxicology requirements. Encompassing integrated toxicology solutions, the offerings encompass automated analyzers, reagents, calibrators, and controls, covering drugs of abuse urine screening. Additionally, the portfolio extends to encompass Liquid Chromatography / Mass Spectrometry (LCMS) analyzers, standards, and reagents.

Spanning a range of requirements, the assortment of analyzers addresses different laboratory specifications, offering options from low to medium throughput bench-top models to high throughput floor models. For those focusing on LCMS in toxicology, the choice between new or refurbished systems from AB Sciex, Agilent, and Shimadzu is available. In case guidance on LCMS method validation or related standards and reagents is needed, assistance can be readily provided.

  • Allergy Testing: Addressing the growing demand for allergy diagnosis and treatment. IgE allergy testing enables laboratories to examine blood samples drawn from patients to assess food, airborne, or blended panels for allergies. This approach proves to be both more streamlined and economically advantageous for primary allergy diagnostics. Moreover, it is the favored choice for conducting allergy tests in pediatric cases.
  • Hematology: Delving into blood-related disorders and abnormalities. Automated hematology analyzers are available in both 3-Diff and 5-Diff configurations, along with reagents, calibrators, and controls. These offerings cater to a wide range of laboratory environments, including physician office labs, CLIA reference labs, and hospital labs.
  • Immunoassay: Uncovering insights into autoimmune conditions and hormone imbalances.
  • Toxicology: Supporting forensic and healthcare professionals with accurate drug testing.

Custom Panels for RT-PCR:

  • Antibiotic Resistance: Identifying antibiotic-resistant strains to guide effective treatment strategies.
  • Nail Fungus: Providing clarity on fungal infections for targeted interventions.
  • STDs: Offering discrete and comprehensive sexually transmitted disease testing.
  • Respiratory, Wound, and UTI Panels: Enabling a holistic approach to diagnosing infections and abnormalities.

Jant Pharmacal can customize your panels according to your target selection and pre-plate to be compatible with your analyzer. More assays available upon request.

Standard Panels:

Standard Lyophilized RT-PCR Panel Kits serve as a comprehensive solution designed to oversee the entire reverse transcription quantitative real-time PCR (RT-qPCR) workflow. They are are pre-made, easy and ready to use. This encompasses every stage, from the extraction of nucleic acids to the crucial steps of reverse transcription and subsequent amplification. It’s important to note that this RUO kit is strictly intended for research purposes and does not carry any medical intent.

  • Respiratory: Diagnosing respiratory infections for timely medical interventions.
  • Gastrointestinal: Assessing gastrointestinal health to identify digestive disorders.
  • Monkeypox, Sexual Health, and Tropical Diseases: Catering to specialized diagnostic needs.

Pharmacogenomics (PGx) Testing:

Pharmacogenomics: Tailoring medication regimens to individual genetic profiles, enhancing treatment efficacy and minimizing adverse reactions.

Jant Pharmacal: Your Partner in Transformation

Jant Pharmacal stands as a trusted ally, offering more than just equipment. With an unwavering commitment to laboratory excellence, it provides an integrated solution to elevate laboratory performance and capabilities. By collaborating with Jant Pharmacal, laboratory technicians can explore and embrace these diversified testing options, ensuring their laboratories remain at the forefront of diagnostic innovation. Check them out here: https://www.jantdx.com/

Pioneering the Path Forward

As inflation challenges traditional business models, laboratories stand on the brink of transformation. By expanding their testing menu beyond the confines of COVID-19, they can chart a new trajectory towards financial resilience. With Jant Pharmacal’s comprehensive support and innovative solutions, laboratories can explore untapped diagnostic territories, unlocking a future of sustainable growth, cutting-edge diagnostics, and enhanced patient care. The path forward is marked by diversification, innovation, and a steadfast commitment to elevating the healthcare landscape.